Search results

Narrow your search

Result types

Showing 1371 - 1380 of 2137 for "Zhong Lun Law Firm" with applied filters

News & Analysis

Anand and Anand launches ‘Digital Group’

20 February 2023 by Anand and Anand - India

In its centenary year, Tier I full-service Intellectual Property firm Anand and Anand today announced the launch of its ‘Digital Group’.

News & Analysis

Korean Tax Law and Regulation Updates for 2023

20 February 2023 by Lee & Ko - South Korea

Korea’s latest tax reforms package was approved by the National Assembly in December 2022, with further details made clear by the Presidential Enforcement Decree which was published in January 2023. Before going into the details of the Korean tax reforms for 2023, it is important to consider the wider global context and domestic political context in which these reforms have been made, in order to understand some of the rationale underlying the reforms.

News & Analysis

SSEK Proudly Announces Brand Refresh

14 February 2023 by SSEK Legal Consultants

SSEK is pleased to announce a brand refresh including a redesign of the firm’s logo, website, and communications. We also have updated our name to SSEK Law Firm.

News & Analysis

Indonesia’s Omnibus Law Focuses on Fintech Innovation

10 February 2023 by Makarim & Taira S - Indonesia

The enactment of Law No. 4 of 2023 on the Development and Reinforcement of the Financial Sector (“the P2SK Law”) has provided fresh air for technological innovation in financial services. At the same time, the P2SK Law also protects consumers and strengthens the financial sector amid rapid digital development. Specifically, we discussed Financial Sector Technological Innovation (Inovasi Teknologi Sektor Keuangan - “ITSK”) and the possibilities for it under the P2SK Law. This advisory is the first of many advisories in the P2SK Law dedicated series.

News & Analysis

Missed deadline: Remedy under the Indian Patent Laws

07 February 2023 by LexOrbis - Manisha Singh (Partner) & Krishna Goyal (Associate)

The process to obtain a patent entails multiple stages from the filing of a patent application to the grant of the patent. There are various deadlines associated with each of these stages, such as the date of filing an application for the grant of patent and the date of filing the Request for Examination (RFE). The Indian Patent Office is very stringent for adherence to these deadlines, and failure to meet them may result in the rejection of a patent application. Thus, it is very important for a patent professional or an Applicant to cautiously meet the to avoid any adverse effect on the application. This article covers the consequences and remedies under the Indian patent laws in case any deadline associated with the patent application is missed.

News & Analysis

Guideline on New Anti-money Laundering Law

05 February 2023 by VILAF - Vietnam

While Vietnam remains a predominantly cash-based economy, its legal frame work on anti-money laundering, according to the Asian Pacific Group on Money Laundering (APG)’s assessment in its Mutual Evaluation Report dated January 2022, is still incomprehensive and limited, which makes the country itself vulnerable to risks of money laundering.

News & Analysis

India: Contemnor to pay INR 2 Crores to the plaintiffs in a patent infringement case

02 February 2023 by Anand and Anand

Pfizer Inc. and its group companies (“Pfizer”) filed a suit bearing no. CS (COMM) No. 442 of 2021 titled as Pfizer Inc. & Ors. v. Triveni Interchem Private Limited & Ors. before the Hon’ble Delhi High Court, for infringement of patent IN 218291 for the compound Palbociclib.

News & Analysis
Image

LAWYER OF THE MONTH - JANUARY 2023

31 January 2023 by asialaw

asialaw's Lawyer of the Month for January 2023 is...

News & Analysis
Image

DEAL OF THE MONTH - JANUARY 2023

31 January 2023 by asialaw

asialaw's Deal of the Month for January 2023 is...

News & Analysis

Advised Cigna Corporation on its Sale of LINA Korea to Chubb Limited

31 January 2023 by Kim & Chang - South Korea

On October 7, 2021, Cigna group entered a stock purchase agreement to sell the equity interests of certain companies operating across seven countries, including LINA Life Insurance Co., Ltd. (“LINA Life”) and Cigna Korea, to Chubb group for USD $5.75 billion in cash (this event is hereby referred to as “the Transaction”). The Transaction was successfully completed on July 1, 2022. Kim & Chang advised Cigna Group in this transaction with respect to due diligence on LINA Life and other divested companies in Korea, review and execution of the stock purchase agreement and other legal advice necessary or required for the transaction.